Company Overview
| Stock Name | Acotec-B |
|---|---|
| Stock Code | 06669 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國創新醫療器械企業,以「介入無植入」為理念,提供血管疾病治療方案,研發藥物塗層球囊(DCB)及血栓抽吸導管等介入醫療器械。 |
| Listing Date | 2021-08-24 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京北京經濟技術開發區宏達北路16號1幢4至5層 |
| Business Address (Hong Kong) | 香港德輔道中188號金龍中心14樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | acotec.cn |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 23.80 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1,000 shares |
| Entry Threshold | HK$ 23,800 |
| Par Value | To be extracted |
| Offer Period | 2021-08-12 to 2021-08-17 |
| Global Offering Shares | 68,633,000 shares |
| HK Public Offer Shares (Initial) | 6,864,000 shares (10.0%) |
| Public Offer Lots (Initial) | 6,864lots (Pool A3,432lots,Pool B3,432lots) |
| International Placing Shares (Initial) | 61,769,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 313,389,171 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 49.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,633,465,400 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 23,800 |
| 2 lots | 2,000 | HK$ 47,600 |
| 3 lots | 3,000 | HK$ 71,400 |
| 4 lots | 4,000 | HK$ 95,200 |
| 5 lots | 5,000 | HK$ 119,000 |
| 6 lots | 6,000 | HK$ 142,800 |
| 7 lots | 7,000 | HK$ 166,600 |
| 8 lots | 8,000 | HK$ 190,400 |
| 9 lots | 9,000 | HK$ 214,200 |
| 10 lots | 10,000 | HK$ 238,000 |
| 12 lots | 12,000 | HK$ 285,600 |
| 14 lots | 14,000 | HK$ 333,200 |
| 16 lots | 16,000 | HK$ 380,800 |
| 18 lots | 18,000 | HK$ 428,400 |
| 20 lots | 20,000 | HK$ 476,000 |
| 25 lots | 25,000 | HK$ 595,000 |
| 30 lots | 30,000 | HK$ 714,000 |
| 35 lots | 35,000 | HK$ 833,000 |
| 40 lots | 40,000 | HK$ 952,000 |
| 45 lots | 45,000 | HK$ 1,071,000 |
| 50 lots | 50,000 | HK$ 1,190,000 |
| 60 lots | 60,000 | HK$ 1,428,000 |
| 70 lots | 70,000 | HK$ 1,666,000 |
| 80 lots | 80,000 | HK$ 1,904,000 |
| 90 lots | 90,000 | HK$ 2,142,000 |
| 100 lots | 100,000 | HK$ 2,380,000 |
| 150 lots | 150,000 | HK$ 3,570,000 |
| 200 lots | 200,000 | HK$ 4,760,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 250 lots | 250,000 | HK$ 5,950,000 |
| 300 lots | 300,000 | HK$ 7,140,000 |
| 350 lots | 350,000 | HK$ 8,330,000 |
| 400 lots | 400,000 | HK$ 9,520,000 |
| 450 lots | 450,000 | HK$ 10,710,000 |
| 500 lots | 500,000 | HK$ 11,900,000 |
| 600 lots | 600,000 | HK$ 14,280,000 |
| 700 lots | 700,000 | HK$ 16,660,000 |
| 800 lots | 800,000 | HK$ 19,040,000 |
| 900 lots | 900,000 | HK$ 21,420,000 |
| 1,000 lots | 1,000,000 | HK$ 23,800,000 |
| 1,500 lots | 1,500,000 | HK$ 35,700,000 |
| 2,000 lots | 2,000,000 | HK$ 47,600,000 |
| 2,500 lots | 2,500,000 | HK$ 59,500,000 |
| 3,432 lots | 3,432,000 | HK$ 81,681,600 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 2.69B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +261% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 7,458,662,269 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 亏损人民幣44.3百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 105 |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 |
|---|---|---|
| Revenue | 124,910 | 193,975 |
| Cost of sales | -18,979 | -30,195 |
| Gross profit | 105,931 | 163,780 |
| Other income and gains, net | 2,964 | 4,645 |
| Selling and distribution expenses | -36,266 | -32,581 |
| Administrative expenses | -20,972 | -72,112 |
| Operating profit | 26,708 | -31,447 |
| Net finance costs | -3,603 | -12,845 |
| Profit before tax | 23,105 | -44,292 |
| Income tax expense | 0 | 0 |
| Profit for the year | 23,105 | -44,292 |
| Profit attributable to owners | 23,105 | -43,842 |
Balance Sheet
| Item | 2019 | 2020 | 2021-03 |
|---|---|---|---|
| Cash and cash equivalents | 31,524 | 147,097 | |
| Trade and bills receivables | 4,437 | 29,518 | |
| Inventories | 32,842 | 28,538 | |
| Total current assets | 73,229 | 218,241 | |
| Total assets | 112,239 | 272,941 | |
| Total current liabilities | 59,189 | 404,124 | |
| Total liabilities | 96,208 | 123,115 | |
| Total equity | 16,031 | 149,826 | |
| Equity attributable to owners | 16,031 | 149,496 | |
| Interest-bearing borrowings | 0 | 20,000 | 144,855 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021-03 |
|---|---|---|---|
| Net cash from operating activities | 19,856 | -8,765 | |
| Net cash from investing activities | -2,317 | -17,735 | |
| Net cash from financing activities | -3,190 | 142,520 | |
| Net increase in cash | 14,349 | 116,020 | |
| Depreciation of PP&E | 2,001 | 937 | 873 |
| Depreciation of right-of-use assets | 1,587 | 4,170 | 1,285 |
| Amortisation of intangible assets | 310 | 254 | 93 |
| Purchase of PP&E | -2,301 | -18,506 | -3,742 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 17.6 |
|---|---|
| First Day Open | HK$ 18.32 |
| First Day Change | -26.05% |
| First Day Volume | 31056400.0 |
| First Day Turnover | 552859000.0 |
| Use of Proceeds | 1、32%(或約489.30百萬港元)將被分配予我們的核心產品;
2、23%(或約351.70百萬港元)將被分配予我們現有產品管線中余下的24款產品;
3、7%(或約107.0百萬港元)將用于擴大生產能力及強化制造能力;
4、24%(或約366.90百萬港元)將獲分配用于為通過(其中包括)內部研發、合作、合并及收購、授權引進或股權投資等方式擴大我們的產品組合提供資金;
5、8%(或約122.30百萬港元)將用于我們的營運資金及一般企業用途;
6、6%(或約91.70百萬港元)將用于償還2021年1月來自硅谷銀行的貸款。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (2)
Joint Bookrunners (4)
Joint Lead Managers (4)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Athos Asia Event Driven Master Fund | 38,817,800 HKD | — | 2.38% | — | 6 months | 2022-02-24 |
| 2 | CPE Investment Wu Limited | 77,659,400 HKD | — | 4.75% | — | 6 months | 2022-02-24 |
| 3 | Dymon Asia Capital (Singapore) Pte. Ltd. | 38,817,800 HKD | — | 2.38% | — | 6 months | 2022-02-24 |
| 4 | Perseverance Asset Management International (Singapore) Pte. Ltd. | 77,659,400 HKD | — | 4.75% | — | 6 months | 2022-02-24 |
| 5 | Primeone Luck Limited | 38,817,800 HKD | — | 2.38% | — | 6 months | 2022-02-24 |
| 6 | The Valliance Fund | 77,659,400 HKD | — | 4.75% | — | 6 months | 2022-02-24 |
| 7 | 保银资产管理有限公司 | 38,817,800 HKD | — | 2.38% | — | 6 months | 2022-02-24 |
| 8 | 达观国际有限公司 | 77,659,400 HKD | — | 4.75% | — | 6 months | 2022-02-24 |
| 9 | 汇添富基金管理股份有限公司 | 155,342,600 HKD | — | 9.51% | — | 6 months | 2022-02-24 |
| 10 | 盘京港景投资基金 | 38,817,800 HKD | — | 2.38% | — | 6 months | 2022-02-24 |
| 11 | 新里程医院集团有限公司 | 38,817,800 HKD | — | 2.38% | — | 6 months | 2022-02-24 |
| 12 | 易方达基金管理有限公司 | 38,817,800 HKD | — | 2.38% | — | 6 months | 2022-02-24 |
| 13 | 中国国际金融股份有限公司 | 77,659,400 HKD | — | 4.75% | — | 6 months | 2022-02-24 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 李靜 | — |
| Company Secretary | 李晨、李菁怡 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 緊隨全球發售完成後,CA Medtech持有本公司50.61%股份,為控股股東;李靜女士被視為持有17.53%股份。 |
|---|




